Book previews

Saturday, August 24, 2013

HHV-6 and the Promise of Ampligen


This experimental drug not only stops HHV-6, it helps AIDS and CFS patients function.

By Neenyah Ostrom
First published in: New York Native, issue #663, January 1, 1996
During 1995, a series of extremely disturbing facts were revealed about the damage Human Herpes Virus 6 (HHV-6) is able to inflict. The virus was linked to the brain and nervous system damage seen in Multiple Sclerosis; scientists warned that HHV-6 is a dangerous contaminant of the blood supply, which is not screened for its presence, and is therefore probably being transmitted via transfusion; HHV-6 was found to be the most common infection in AIDS patients, rather than CMV as was previously assumed; it was implicated as a cause of the blinding AIDS retinitis; Italian research linked HHV-6 (Variant A) not only to AIDS and Chronic Fatigue Syndrome, but also to AIDS-associated Kaposi's sarcoma; and, perhaps most importantly, HHV-6 has been shown to be present in the lymph nodes of AIDS patients right from the beginning of their disease.
All of this has resulted in a growing number of scientists who routinely refer to HHV-6 as the "AIDS co-factor."
All of this sounds pretty grim. But there is also good news to report from 1995's scientific endeavors: There is a non-toxic, experimental drug that appears to be able to stop the virus cold in its tracks. The drug is Ampligen, a special form of RNA (the sister molecule to DNA, of which most viruses are composed); it interferes with HHV-6's ability to grow.
The bad news is that the seemingly effective and non-toxic Ampligen, for some impossible-to-understand reason, has yet to be approved by the Food and Drug Administration.
In clinical trials, Ampligen not only inhibits the growth of HHV-6 in tissue culture, but also appears to produce long-term improvement in patients with CFS-who are known to have active HHV-6 infections.
Two recent studies demonstrating Ampligen's effectiveness against HHV-6, performed by some of the leading researchers in the field of the virology of HHV-6 and the clinical treatment of CFS, have added significant ammunition to arguments that Ampligen should be approved by the FDA immediately.
Dharam V. Ablashi was lead author on the scientific report, published in the journal in vivo, which showed that Ampligen inhibited HHV-6 from growing in cells in tissue culture. In addition to other collaborators, well-established CFS researchers Robert Suhadolnik and Anthony Komaroff were investigators in this study.1
Ablashi and colleagues began by pointing out that, while it is believed most people are infected with HHV-6, "many different strains of the virus, comprising of two variants (the A and B variants), with different biologic properties, have been identified." And while HHV-6 has been associated with the generally-mild childhood illness roseola, active HHV-6 infection has also been reported in a number of conditions "known or suspected to be associated with immunological dysfunction." That list, according to Ablashi and colleagues, includes AIDS, Hodgkin's disease (lymphoma), autoimmune disorders like lupus, graft-versus-host disease, and Chronic Fatigue Syndrome.2
HHV-6's possible role in AIDS is particularly troubling, Ablashi and co-workers noted, since, "Like human immunodeficiency virus-1 (HIV-1), HHV-6 is tropic for CD4-positive T-cells; dual infection of CD4-positive cells with both HIV-1 and HHV-6 greatly enhances the rate of CD4-positive cell death." They continued, "Whether the synergistic cytopathic effects of HHV-6 and HIV-1 contributes to pathology or morbidity in HIV infected patients remains to be determined." In other words, does being infected with HHV-6 in addition to HIV indicate a worse prognosis than being infected with HIV alone? The experimental drug Ampligen, Ablashi and colleagues explain, is a mis-matched, double-stranded RNA that has "broad spectrum antiviral and immune modulating activity." They note that when used in combination with "a low dose of AZT," Ampligen "significantly reduced the cytopathic effect inducted by HIV-1" in cell cultures.
As Ablashi recently told the Native, however, giving AZT to an HHV-6 infected individual can, based on laboratory findings, have an extremely deleterious effect, since AZT not only increases the growth of the virus, but increases its cell-killing ability. (See Native #662, December 25, 1995, for the complete Ablashi interview.) Ampligen has also shown a positive effect on the clinical conditions of CFS and AIDS patients, these investigators point out. In particular, a long-term trial of Ampligen treatment of CFS patients resulted in "improved performance on exercise testing as well as improved quality of life, compared to those using a placebo." Therefore, "Since HHV-6 reactivation is frequently seen in CFS infection and since Ampligen treatment seemed to produce a clinical benefit in patients with CFS, we conducted in vitro [laboratory] studies to determine whether Ampligen had antiviral effects against HHV-6."
Cells infected with the GS strain of variant A HHV-6-the type most commonly detected in patients with CFS, AIDS, and other immunocompromised conditions-were treated with Ampligen while being grown in tissue culture, before and after being infected with HHV-6. Cells that were pretreated with Ampligen before infection with HHV-6 showed "substantial inhibition of virus replication, ranging from 45.7-78.3 percent."
A second variation of the experiment was the most successful: When cells were both pre-treated with Ampligen before HHV-6 infection, and then grown in culture with Ampligen present, as well, "inhibition of virus replication was nearly complete," Ablashi and co-workers reported.
In a third variation of the experiment, cells were not pretreated with Ampligen, but treated only at the time of viral infection; no Ampligen was added thereafter to the cultures. Even under these conditions, there was inhibition of viral replication, ranging from 45.7 to 89.1 percent.
The fourth permutation in this series of experiments was the also quite successful: When the cells were not pre-treated but were treated continuously with Ampligen after HHV-6 infection, there was a "dose related inhibition of virus replication, ranging from 95.5-91.3 percent at three different concentrations (50, 100, and 200 micrograms/milliliter)," Ablashi and colleagues report. A concentration of only ten micrograms/milliliter was not enough to inhibit HHV-6 infection, they found.
Perhaps the best news in this study is that inhibition of HHV-6 with Ampligen resulted in absolutely no toxicity to the cells; they remained "90 percent viable," i.e., alive.3 This study indicates that Ampligen appears not only to stop replication of the virus, but also to stop HHV-6 from maturing once it is in the cell.
But do those effects, in the lab, translate into clinical improvement when people with active HHV-6 infections are treated with Ampligen? In 1995, a study was published that showed long-term improvement in patients with Chronic Fatigue Syndrome who were treated with Ampligen. Ablashi was an investigator in this study, as were Ampligen co-inventor William Carter, CFS researchers Daniel Peterson, David R. Strayer, Robert J. Suhadolnik, Sheila Bastien, HHV-6 researcher Berch Henry, and others.4
The answer to the question of whether Ampligen improved the health of CFS patients, who are known to have active HHV-6 infections, was yes. Improvement was noted in patients' Karnofsky Performance Scale (KPS), a measure of ability to perform daily activities like taking care of oneself; memory and IQ improved; exercise tolerance was increased; and there was a measurable reduction of HHV-6 activity.
The Strayer paper reported not only these marked improvements in CFS patients treated with Ampligen, but that they were sustained over the long term.
Fifteen CFS patients, all of whom met the Centers for Disease Control criteria for CFS, participated in the experiment. Their mean age was 44, and 73 percent were women. These patients had been sick for an average of 33 months. "All 15 patients were functionally impaired by their illness as evidenced by their mean baseline Karnofsky Performance Score of 47 (range 20-60)," Strayer and colleagues reported. A KPS score of 100 is considered normally functional. There were two dose regimens administered to the study participants. Initially, they received 200 milligram of Ampligen intravenously twice a week "for variable periods of time"; then, the dosage was increased to 400 milligrams twice a week. Some patients' doses were increased to 400 milligrams three times a week.
Patients were monitored for active Human Herpes Virus 6 infection by blood cultures, which were "observed periodically for the formation of giant cells characteristic of herpesvirus infection," according to Strayer et al. HHV-6 itself was found in those giant cells, and the percentage of those cells infected with Variant A HHV-6 (the GS strain) was determined.
Some patients had more than ten percent "giant cells" in their cultured blood cells, scored as "two"; those with between 0 percent and ten percent scored as "one"; and those with no giant cells scored as "zero."5
No patient in the study dropped out because of toxicity from the drug. At the beginning of Ampligen therapy, patients reported an increase in flu-like symptoms (muscle and headaches), but those symptoms "typically abated" as treatment continued.
"There were no clinically significant alterations of coagulation, blood chemistry values, white blood counts, or liver and renal function test values throughout the course of this study," Strayer and colleagues reported. "Only two adverse events, one case each of feeling lightheaded and facial flushing, were reported as definitely related to Ampligen. There were no severe adverse events attributed to Ampligen." One patient became anemic because of the amount of blood drawn for testing, and was treated with an iron supplement. There were also changes in laboratory blood test values-red blood cell count, hemoglobin, numbers of different types of lymphocytes and platelets-noted during this study. Blood clotting remained normal, as did urinalysis.
Perhaps the most striking improvement was measured by the Karnofsky Performance score (KPS), as Strayer and co-workers explained: "Patients entering the study were significantly incapacitated, with a mean Karnofsky performance score (KPS) of 47. At a KPS level of 40-50 an individual is significantly disabled and requires special care or considerable assistance to perform normal activities of daily living. Self-care is limited and 50 percent or more of the individual's's waking hours are spent confined to bed and/or chair. The average score improved to 67 after 12 weeks of Ampligen therapy. A KPS score of 60-70 describes an individual able to care for most needs with no or only occasional assistance, but unable to carry out any work activities.
"KPS showed sustained improvements through 60 weeks, reaching 80 by 24 weeks and 85 by 60 weeks. An 80 KPS score describes a person capable of normal activity with effort. Some signs and symptoms of disease are still present but no special care is required. The [statistical analysis performed] strongly suggested that the continued increase in KPS during the first 24 weeks of Ampligen therapy was statistically significant."6
Ampligen also reduced the presence of the giant cells indicative of HHV-6 infection. All 14 patients were positive for giant cells before Ampligen treatment. The number of such cells increased during Ampligen treatment in 50 percent of the patients at eight weeks, and in 77 percent at 16 weeks. Four of the patients actually became culture-negative for HHV-6 during Ampligen treatment. In other words: Ampligen stops HHV-6.
In fact, this not-yet-approved, non-toxic drug appears to inhibit the growth of the "AIDS cofactor" completely.
In addition to the other clinical improvements noted during Ampligen treatment, cognitive functioning also increased. Memory scores increased as much as 23 to 45 percent, as did IQ scores.
Only two of the patients in the study failed to experience all of these improvements in clinical status, for unknown reasons. The clinical effects of Ampligen, like its ability to inhibit HHV-6's growth, appeared to be dose-dependent; the most dramatic improvements in daily functioning, Strayer and co-authors point out, occurred after Ampligen dosage was increased to 400 milligrams.
Strayer and colleagues speculate that these clinical improvements could be associated with Ampligen's inhibition of HHV-6.
"Reduced ability to obtain giant cells in short term culture of blood mononuclear cells was noted during Ampligen treatment," they reported. "In eight cases, giant cells were shown to express HHV-6, utilizing specific monoclonal antibodies. This could have resulted from a restoration of normal lymphokine balance, from direct inhibition of virus replication, or from elimination of HHV-6 expressive cells by immune mechanisms. Giant cell formation in this system is associated with HHV-6 infection, but it is not known whether HHV-6 expression or giant cell formation contributes to CFS symptomatology. However, recent studies show that Ampligen can inhibit in vitro replication of HHV-6...."
Why has this seemingly safe, effective drug not been approved by the FDA?
Is it because a treatment that proves effective for both CFS and AIDS would highlight the connection between the two syndromes? References
  1. Ablashi, D.V. et al.; "Ampligen Inhibits Human Herpesvirus-6 in Vitro"; in vivo 8:587, 1994.
  2. Ibid.
  3. Ablashi et al., op cit.
  4. Strayer, David R. et al.; "Long Term Improvements in Patients With Chronic Fatigue Syndrome Treated With Ampligen"; Journal of Chronic Fatigue Syndrome 1(1):35, 1995.
  5. Ibid.
  6. Strayer et al., op cit

A.M. Kogelnik on Treating HHV-6 with Vanganciclovir


http://www.cfids-cab.org/rc/Kogelnik.pdf
Dr. Andreas M. Kogelnik, MD, PhD discusses the current state of research in the area of chronic fatigue syndrome from a molecular science perspective and touch on advances in clinical diagnostics and treatment directions.

Human Herpesvirus 6 Genome Integration



"In our opinion, antiviral drugs should still be considered the first therapeutic approach in the case of clinical symptoms concomitant with a high HHV-6 load occurring in a transplant recipient."

Human Herpesvirus 6 Genome Integration: A Possible Cause of Misdiagnosis of Active Viral Infection?

David Boutolleau,1,3 Henri Agut,1 and Agnès Gautheret-Dejean1,2
1Laboratoire de Virologie, Université Pierre et Marie Curie–Paris 6, EA 2387, Groupe Hospitalier Pitié-Salpêtrière, and 2Laboratoire de Microbiologie, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, and 3Laboratoire de Bactériologie-Virologie, Faculté de Médecine Paris Sud, Centre Hospitalo–Universitaire de Bicêtre, Le Kremlin–Bicêtre, France

Frontotemporal Lobar Degeneration and HHV-6


"Pick's disease, a type of frontal lobe degeneration, was first recognized clinically in 1892.1 However, frontal lobe degenerative dementia was considered rare until 1987 when 12.5% of autopsy cases from a series of patients with dementia were reported to have degeneration of the frontal lobes with non-Alzheimer's pathology.2 Since then frontotemporal lobar degeneration (FTLD) has become recognized as the third most common cause of cortical dementia behind Alzheimer's disease and Lewy body disease. In 1998 the consensus guidelines for the clinical diagnosis of FTLD were published." http://www.dcmsonline.org/jax-medicine/2000journals/February2000/ftld.htm
"Circumscribed cerebral atrophy of the frontal and anterior temporal lobes, also called lobar atrophy, is the gross pathological hallmark of FTLD." http://www.dcmsonline.org/jax-medicine/2000journals/February2000/ftld.htm
Contrary to conventional wisdom, FTLD may not be primarily a genetic disorder:
"In one study about 45% of FTLD patients have family members with a similar disorder.7 Genetic mutations in the tau protein on chromosome 17 have been identified in several families. Most of these mutations have been shown to increase the proportion of an isoform of tau called 4-repeat tau.8 However, it is clear that most cases in clinical practice don't have one of these mutations on chromosome 17. In fact in more than 50 consecutive cases, we have identified none with a chromosome 17 mutation. Apolipoprotein E4 allele (which has been shown to be a risk factor for AD) does not appear to be associated with FTLD." http://www.dcmsonline.org/jax-medicine/2000journals/February2000/ftld.htm

HHV-6 and B-cells



Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6.

L Flamand, I Stefanescu, D V Ablashi, and J Menezes
J Virol. 1993 November; 67(11): 6768–6777
"Interestingly, human B-cells appear to be particularly susceptible to HHV-6 infection in vitro only if they have been previously infected with EBV." http://www.ncbi.nlm.nih.gov/pmc/articles/PMC238118/?page=1
"The detection of HHV-6 genomic sequences in some B-cell neoplasias and the potential of an HHV-6 genomic segment in transforming rodent cells suggests a possible, if indirect, role for the virus in certain cancers."
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC238118/?page=2
"It can tentatively be hypothesized that HHV-6 activates EBV in B-cells by inducing the immediate-early transactivator, Zebra." http://www.ncbi.nlm.nih.gov/pmc/articles/PMC238118/?page=7
"By inducing EBV, HHV-6 may, therefore, contribute to the increase of the B-cell pool infected with EBV, thereby increasing the chances of developing an EBV-related lymphoma. Taken together the present study illustrates the inteactions between two viruses, both belonging to the same family, which can infect B lymphocytes."
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC238118/?page=8
"We have demonstrated that infection of EBV genome-positive cells by HHV-6 leads to reactivation of EBV."
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC238118/?page=8

HHV-6 activates HERV-K18

Ancient Retrovirus May Contribute to Chronic Fatigue Syndrome, Multiple Sclerosis and Autoimmunity

Smoldering Infections of Two Common Viruses EBV and HHV-6 Cause Inherited Retrovirus Genes to Activate
BALTIMORE, MD--(Marketwire - June 23, 2008) - Brigitte Huber, PhD, of the Tufts University School of Medicine, presented evidence at a medical conference that suggested that a reactivated ancient retrovirus embedded in the human genome may be active in chronic fatigue syndrome (CFS) and multiple sclerosis (MS) patients. Danish scientists at the same conference suggested that the activation of this retrovirus, dormant in healthy individuals, could be the reason why autoimmune conditions worsen with viral infections.
Chronic Fatigue Syndrome and Multiple Sclerosis Patients at Increased Risk From the Effects of HERV-K18 Activation
"Patients with profoundly fatiguing diseases such as MS and CFS may be particularly susceptible to HERV-K18 activation," said Dr. Huber. The announcement was made at the International Symposium on Viruses in CFS and Post-Viral Fatigue, a satellite conference of the 6th International Conference on HHV-6 & 7. Using an SNP-based genotyping method, Dr. Huber found that both MS and CFS patients (whose illness had been triggered by infectious mononucleosis) were at a higher relative risk for containing HERV-K18 variants known to induce superantigen activity. Superantigens are proteins that are able to induce a strong undifferentiated T-cell response believed to deplete the immune system over time.
Viral activity and/or immune activation has been shown to trigger HERV-K18 activity. Both Epstein-Barr virus infection (infectious mononucleosis) and interferon-alpha administration are associated with HERV-K18 activity. "HHV-6 activates HERV-K18 as well," said Danish investigator Per Hollsberg, MD and professor from the University of Aarhus In Denmark. His PhD student Vanda Lauridsen Turcanova presented this data at the same conference. "Furthermore, this retrovirus activation may have important consequences for autoimmunity," he added.
HERV-K18 activation may be the endpoint of an HHV6/EBV interferon pathway operating in both MS and CFS. HHV-6 is being investigated as a co-factor in both diseases. Other retroviruses, HERV-H and HERV-W, have been implicated in MS by other researchers. Over 75% of MS patients meet the criteria for CFS. Fatigue is often the most disabling symptom for MS patients. The two diseases also share characteristics such as grey matter atrophy, impaired cerebral glucose metabolism, autonomic nervous system activity and altered patterns of brain activity.
Dr. Huber's study suggests that endogenous retroviral activation in CFS and MS could produce some of the symptoms associated with both diseases. She has received a National Institutes of Health (NIH) grant to study these issues. Per Hollsberg has done extensive research on the role of EBV and HHV-6 in multiple sclerosis.

Antiphospholipid Syndrome Associated With Human Herpesvirus-6 Infection

"The case of a patient with basal ganglia infarction associated with primary human herpesvirus-6 infection is reported. Anticardiolipin antibody immunoglobulin G was elevated after human herpesvirus-6 infection and then decreased gradually. The transient elevation in the antiphospholipid antibody level suggests that the human herpesvirus-6 infection can induce antiphospholipid syndrome, thus resulting in a cerebral infarction."
Pediatric Neurology Volume 37, Issue 6 , Pages 449-451, December 2007


If HHV-6 is the real cause of AIDS, here are some of the implications:

1. HIV is a massive scientific fraud. Something akin to a Ponzi scheme. Scientists who challenged the HIV theory of AIDS (the ones who have been thuggishly censored and silenced) turn out to be on the money.

2. Chronic Fatigue Syndrome and Autism (and many other so-called HHV-6 related mysterious epidemics) are part of the so-called AIDS epidemic.  Chronic Fatigue Syndrome and Autism both are clearly the results of the ravages of HHV-6.

3. AIDS and Chronic Fatigue Syndrome has been artificially and politically separated into two epidemics. We are living in a period of CFS/AIDS apartheid. So-called AIDS patients have to sit in the back of the HHV-6 epidemic bus while the befuddled HHV-6/CFS patients and HHV-6/Autism victims sit up front. Nobody is well-served.

4. AIDS is not a sexually transmitted disease. That paradigm has set a scapegoating and antigay agenda in place that the public thinks is solidly based on science. It is only based on homophobic and racist nosology, epidemiology and virology. The scientists behind the paradigm are charlatans and crooks.

5. The Centers for Disease Control in Atlanta and the Pasteur Institute in Paris have a great deal in common with the institutions of Nazi medicine. For Blacks, everything these institutions have done in the name of AIDS really constitutes a second Tuskegee Syphilis Experiment.

Elements of a Scientific Ponzi Scheme like the Montagnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up

A scientific Ponzi scheme begins with a central seminal or foundational scientific fraud and is  sometimes built on an infrastructure of smaller scientific frauds. Like the fake dividends issued in a strictly financial Ponzi scheme, a scientific Ponzi scheme issues fake dividends in the form of ongoing fraud-based research often framed as "breakthroughs" and bogus extrapolations which make it look like everything is above board and that what, in reality, is scientific fraud, appears to the rest of the scientific community and the public as good faith progress.

A classic scientific Ponzi scheme like the Montgnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up include elements like these:

1. Nosological fraud.

2. Epidemiological fraud.

3. Virological fraud.

4. Treatment fraud.

5. Public health policy fraud.

6. Concealment of negative scientific data and paradigm-challenging anomalies.

7.  Use of an elite network of "old boys" and pseudo-activist provocateurs to censor critics and whistleblowers.

8. Chronic obscurantism.

9. If necessary, vigilantism and witch-hunts against any intellectuals, scientists, or citizens who constitute any form of resistance to the Ponzi scheme.

10. A subservient scientific press that is used as a conveyor belt for the Ponzi scheme's propaganda.

Everything always looks like it is working perfectly in a Ponzi scheme, until the moment comes when someone look at the books and blows the whistle.  Hopefully, that game-changing moment for the Montagnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up is coming soon.


Dr. Jose Montoya on Treating CFS and HHV-6

http://www.youtube.com/watch?v=Riybtt6SChU

Statement from Treatment Center for Chronic Fatigue Syndrome Implicates HHV-6 in Chronic Fatigue Syndrome:

"We have, along with a team of investigators at this Center, accumulated strong evidence that CFS is caused by persistent herpes virus infection (Epstein-Barr virus, Cytomegalovirus and Herpes virus 6), singly or in combination. This infection is treated by specific antiviral medicines." http://www.treatmentcenterforcfs.com/index.html
A Paradigm Linking Herpesvirus Immediate Early Gene Expression Apoptosis and Myalgic Encephalomyelitis, Chronic Fatigue Syndrome (pdf)


If HHV-6 is the real cause of AIDS, here are some of the implications:

1. HIV is a massive scientific fraud. Something akin to a Ponzi scheme. Scientists who challenged the HIV theory of AIDS (the ones who have been thuggishly censored and silenced) turn out to be on the money.

2. Chronic Fatigue Syndrome and Autism (and many other so-called HHV-6 related mysterious epidemics) are part of the so-called AIDS epidemic.  Chronic Fatigue Syndrome and Autism both are clearly the results of the ravages of HHV-6.

3. AIDS and Chronic Fatigue Syndrome has been artificially and politically separated into two epidemics. We are living in a period of CFS/AIDS apartheid. So-called AIDS patients have to sit in the back of the HHV-6 epidemic bus while the befuddled HHV-6/CFS patients and HHV-6/Autism victims sit up front. Nobody is well-served.

4. AIDS is not a sexually transmitted disease. That paradigm has set a scapegoating and antigay agenda in place that the public thinks is solidly based on science. It is only based on homophobic and racist nosology, epidemiology and virology. The scientists behind the paradigm are charlatans and crooks.

5. The Centers for Disease Control in Atlanta and the Pasteur Institute in Paris have a great deal in common with the institutions of Nazi medicine. For Blacks, everything these institutions have done in the name of AIDS really constitutes a second Tuskegee Syphilis Experiment.

Elements of a Scientific Ponzi Scheme like the Montagnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up

A scientific Ponzi scheme begins with a central seminal or foundational scientific fraud and is  sometimes built on an infrastructure of smaller scientific frauds. Like the fake dividends issued in a strictly financial Ponzi scheme, a scientific Ponzi scheme issues fake dividends in the form of ongoing fraud-based research often framed as "breakthroughs" and bogus extrapolations which make it look like everything is above board and that what, in reality, is scientific fraud, appears to the rest of the scientific community and the public as good faith progress.

A classic scientific Ponzi scheme like the Montgnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up include elements like these:

1. Nosological fraud.

2. Epidemiological fraud.

3. Virological fraud.

4. Treatment fraud.

5. Public health policy fraud.

6. Concealment of negative scientific data and paradigm-challenging anomalies.

7.  Use of an elite network of "old boys" and pseudo-activist provocateurs to censor critics and whistleblowers.

8. Chronic obscurantism.

9. If necessary, vigilantism and witch-hunts against any intellectuals, scientists, or citizens who constitute any form of resistance to the Ponzi scheme.

10. A subservient scientific press that is used as a conveyor belt for the Ponzi scheme's propaganda.

Everything always looks like it is working perfectly in a Ponzi scheme, until the moment comes when someone look at the books and blows the whistle.  Hopefully, that game-changing moment for the Montagnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up is coming soon.


HHV-6 and CMV

Presence of Human Herpes Virus 6 (HHV6) in pediatric lymphomas: impact on clinical course and association with cytomegalovirus infection

"The presence of HHV6 can be considered as a predicting indicator of cellular immunosuppression preceding the onset of CMV infection which may result in a severe outcome among pediatric lymphoma patients. "
http://www.virologyj.com/content/7/1/287


If HHV-6 is the real cause of AIDS, here are some of the implications:

1. HIV is a massive scientific fraud. Something akin to a Ponzi scheme. Scientists who challenged the HIV theory of AIDS (the ones who have been thuggishly censored and silenced) turn out to be on the money.

2. Chronic Fatigue Syndrome and Autism (and many other so-called HHV-6 related mysterious epidemics) are part of the so-called AIDS epidemic.  Chronic Fatigue Syndrome and Autism both are clearly the results of the ravages of HHV-6.

3. AIDS and Chronic Fatigue Syndrome has been artificially and politically separated into two epidemics. We are living in a period of CFS/AIDS apartheid. So-called AIDS patients have to sit in the back of the HHV-6 epidemic bus while the befuddled HHV-6/CFS patients and HHV-6/Autism victims sit up front. Nobody is well-served.

4. AIDS is not a sexually transmitted disease. That paradigm has set a scapegoating and antigay agenda in place that the public thinks is solidly based on science. It is only based on homophobic and racist nosology, epidemiology and virology. The scientists behind the paradigm are charlatans and crooks.

5. The Centers for Disease Control in Atlanta and the Pasteur Institute in Paris have a great deal in common with the institutions of Nazi medicine. For Blacks, everything these institutions have done in the name of AIDS really constitutes a second Tuskegee Syphilis Experiment.

Elements of a Scientific Ponzi Scheme like the Montagnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up

A scientific Ponzi scheme begins with a central seminal or foundational scientific fraud and is  sometimes built on an infrastructure of smaller scientific frauds. Like the fake dividends issued in a strictly financial Ponzi scheme, a scientific Ponzi scheme issues fake dividends in the form of ongoing fraud-based research often framed as "breakthroughs" and bogus extrapolations which make it look like everything is above board and that what, in reality, is scientific fraud, appears to the rest of the scientific community and the public as good faith progress.

A classic scientific Ponzi scheme like the Montgnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up include elements like these:

1. Nosological fraud.

2. Epidemiological fraud.

3. Virological fraud.

4. Treatment fraud.

5. Public health policy fraud.

6. Concealment of negative scientific data and paradigm-challenging anomalies.

7.  Use of an elite network of "old boys" and pseudo-activist provocateurs to censor critics and whistleblowers.

8. Chronic obscurantism.

9. If necessary, vigilantism and witch-hunts against any intellectuals, scientists, or citizens who constitute any form of resistance to the Ponzi scheme.

10. A subservient scientific press that is used as a conveyor belt for the Ponzi scheme's propaganda.

Everything always looks like it is working perfectly in a Ponzi scheme, until the moment comes when someone look at the books and blows the whistle.  Hopefully, that game-changing moment for the Montagnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up is coming soon.


Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection.

Pascale Bonnafous, David Boutolleau, Lieve Naesens, Claire Deback, Agnès Gautheret-Dejean, Henri Agut Université Pierre et Marie Curie-Paris 6, EA2387, Groupe Hospitalier Pitié-Salpêtrière, 83 boulevard de l’Hôpital, F-75013 Paris, France.
Cidofovir (CDV) was used for in vitro selection of a human herpesvirus 6 (HHV-6) mutant with decreased susceptibility to this drug. The resulting mutant was highly resistant to CDV as compared to its sensitive counterpart (inhibitory concentration 50%(IC(50)): 213muM versus 1.8muM). Its replication fitness was not impaired. Genotypic characterization of the resistant virus revealed a mutation in the U38 gene encoding the viral DNA polymerase. The resulting R798I amino acid change was located in the conserved domain VII close to the highly conserved motif KKRY interacting with the DNA primer-template duplex, and is likely responsible for the high-level resistance to CDV, even though a definite virological and/or biochemical confirmation is required. The possible emergence of such changes in HHV-6 DNA polymerase in patients receiving CDV therapy should be taken into account in the treatment of HHV-6 infections.
http://lib.bioinfo.pl/pmid:18241936


If HHV-6 is the real cause of AIDS, here are some of the implications:

1. HIV is a massive scientific fraud. Something akin to a Ponzi scheme. Scientists who challenged the HIV theory of AIDS (the ones who have been thuggishly censored and silenced) turn out to be on the money.

2. Chronic Fatigue Syndrome and Autism (and many other so-called HHV-6 related mysterious epidemics) are part of the so-called AIDS epidemic.  Chronic Fatigue Syndrome and Autism both are clearly the results of the ravages of HHV-6.

3. AIDS and Chronic Fatigue Syndrome has been artificially and politically separated into two epidemics. We are living in a period of CFS/AIDS apartheid. So-called AIDS patients have to sit in the back of the HHV-6 epidemic bus while the befuddled HHV-6/CFS patients and HHV-6/Autism victims sit up front. Nobody is well-served.

4. AIDS is not a sexually transmitted disease. That paradigm has set a scapegoating and antigay agenda in place that the public thinks is solidly based on science. It is only based on homophobic and racist nosology, epidemiology and virology. The scientists behind the paradigm are charlatans and crooks.

5. The Centers for Disease Control in Atlanta and the Pasteur Institute in Paris have a great deal in common with the institutions of Nazi medicine. For Blacks, everything these institutions have done in the name of AIDS really constitutes a second Tuskegee Syphilis Experiment.

Elements of a Scientific Ponzi Scheme like the Montagnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up

A scientific Ponzi scheme begins with a central seminal or foundational scientific fraud and is  sometimes built on an infrastructure of smaller scientific frauds. Like the fake dividends issued in a strictly financial Ponzi scheme, a scientific Ponzi scheme issues fake dividends in the form of ongoing fraud-based research often framed as "breakthroughs" and bogus extrapolations which make it look like everything is above board and that what, in reality, is scientific fraud, appears to the rest of the scientific community and the public as good faith progress.

A classic scientific Ponzi scheme like the Montgnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up include elements like these:

1. Nosological fraud.

2. Epidemiological fraud.

3. Virological fraud.

4. Treatment fraud.

5. Public health policy fraud.

6. Concealment of negative scientific data and paradigm-challenging anomalies.

7.  Use of an elite network of "old boys" and pseudo-activist provocateurs to censor critics and whistleblowers.

8. Chronic obscurantism.

9. If necessary, vigilantism and witch-hunts against any intellectuals, scientists, or citizens who constitute any form of resistance to the Ponzi scheme.

10. A subservient scientific press that is used as a conveyor belt for the Ponzi scheme's propaganda.

Everything always looks like it is working perfectly in a Ponzi scheme, until the moment comes when someone look at the books and blows the whistle.  Hopefully, that game-changing moment for the Montagnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up is coming soon.


The T-cell Killer HHV-6 May Not Even Need HIV to Destroy The Cells That Prevent Opportunistic Infections

http://hhv6.jottit.com/hhv-6_may_not_need_hiv_to_cause_aids


If HHV-6 is the real cause of AIDS, here are some of the implications:

1. HIV is a massive scientific fraud. Something akin to a Ponzi scheme. Scientists who challenged the HIV theory of AIDS (the ones who have been thuggishly censored and silenced) turn out to be on the money.

2. Chronic Fatigue Syndrome and Autism (and many other so-called HHV-6 related mysterious epidemics) are part of the so-called AIDS epidemic.  Chronic Fatigue Syndrome and Autism both are clearly the results of the ravages of HHV-6.

3. AIDS and Chronic Fatigue Syndrome has been artificially and politically separated into two epidemics. We are living in a period of CFS/AIDS apartheid. So-called AIDS patients have to sit in the back of the HHV-6 epidemic bus while the befuddled HHV-6/CFS patients and HHV-6/Autism victims sit up front. Nobody is well-served.

4. AIDS is not a sexually transmitted disease. That paradigm has set a scapegoating and antigay agenda in place that the public thinks is solidly based on science. It is only based on homophobic and racist nosology, epidemiology and virology. The scientists behind the paradigm are charlatans and crooks.

5. The Centers for Disease Control in Atlanta and the Pasteur Institute in Paris have a great deal in common with the institutions of Nazi medicine. For Blacks, everything these institutions have done in the name of AIDS really constitutes a second Tuskegee Syphilis Experiment.

Elements of a Scientific Ponzi Scheme like the Montagnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up

A scientific Ponzi scheme begins with a central seminal or foundational scientific fraud and is  sometimes built on an infrastructure of smaller scientific frauds. Like the fake dividends issued in a strictly financial Ponzi scheme, a scientific Ponzi scheme issues fake dividends in the form of ongoing fraud-based research often framed as "breakthroughs" and bogus extrapolations which make it look like everything is above board and that what, in reality, is scientific fraud, appears to the rest of the scientific community and the public as good faith progress.

A classic scientific Ponzi scheme like the Montgnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up include elements like these:

1. Nosological fraud.

2. Epidemiological fraud.

3. Virological fraud.

4. Treatment fraud.

5. Public health policy fraud.

6. Concealment of negative scientific data and paradigm-challenging anomalies.

7.  Use of an elite network of "old boys" and pseudo-activist provocateurs to censor critics and whistleblowers.

8. Chronic obscurantism.

9. If necessary, vigilantism and witch-hunts against any intellectuals, scientists, or citizens who constitute any form of resistance to the Ponzi scheme.

10. A subservient scientific press that is used as a conveyor belt for the Ponzi scheme's propaganda.

Everything always looks like it is working perfectly in a Ponzi scheme, until the moment comes when someone look at the books and blows the whistle.  Hopefully, that game-changing moment for the Montagnier-Agut HIV Fraud Ponzi Scheme and HHV-6 Cover-up is coming soon.


Blog Archive

Popular Posts in the Last 30 Days

You can support us by listening to these songs by Charles Ortleb on Spotify.

cfs book scrib promo

Previous HHV-6 University Reports

ad for cfs book

Audible CFS book

Closing Argument Audible

African Swine Fever Novel Audible

Stonewall Audible